WASHINGTON (Reuters) -The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach two million people over three years.

The company will offer the long-acting HIV prevention drug to the Global Fund and the U.S. government's PEPFAR program without profit, government and company officials said at a news briefing.

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said in July they had finalized plans to supply the drug to low-income countries, despite the absence of funding from the U.S. President’s Emergency Plan for AIDS Relief, or PEPFAR, an initiative aimed at addressing the global HIV/AIDS epidemic.

Jeremy Lewin, senior State Department official fo

See Full Page